[
    {
        "question": "What is the Revenue of Microsoft?",
        "documents": "\n\"\"\" ID: MTg2\n                        Text: •\nXbox content and services revenue decreased 3%.\n \n•\nSearch and news advertising revenue excluding traffic acquisition costs increased 11%.\nIndustry Trends\n \nOur industry is dynamic and highly competitive, with frequent changes in both technologies and business models. Each industry shift is an opportunity to\n \nconceive new products, new technologies, or new ideas that can further transform the industry and our business. At Microsoft, we push the boundaries of\n \nwhat is possible through a broad range of research and development activities that seek to identify and address the changing demands of customers and\n \nusers, industry trends, and competitive forces.\n40\n                        ExternalSourceName: \n                        Source: MICROSOFT\n                        AdditionalMetadata: 2023_10K_39_2874\n                        \n\"\"\"\n\n\n\"\"\" ID: MTg1\n                        Text: manufacturing, marketing, and selling our other products and services; and income taxes.\nHighlights from fiscal year 2023 compared with fiscal year 2022 included:\n•\nMicrosoft Cloud revenue increased 22% to $111.6 billion.\n•\nOffice Commercial products and cloud services revenue increased 10% driven by Office 365 Commercial growth of 13%.\n•\nOffice Consumer products and cloud services revenue increased 2% and Microsoft 365 Consumer subscribers increased to 67.0 million.\n•\nLinkedIn revenue increased 10%.\n•\nDynamics products and cloud services revenue increased 16% driven by Dynamics 365 growth of 24%.\n•\nServer products and cloud services revenue increased 19% driven by Azure and other cloud services growth of 29%.\n•\nWindows original equipment manufacturer licensing (“Windows OEM”) revenue decreased 25%.\n•\nDevices revenue decreased 24%.\n•\nWindows Commercial products and cloud services revenue increased 5%.\n•\nXbox content and services revenue decreased 3%.\n \n•\n                        ExternalSourceName: \n                        Source: MICROSOFT\n                        AdditionalMetadata: 2023_10K_39_1959\n                        \n\"\"\"\n\n\n\"\"\" ID: MjA2\n                        Text: Productivity and Business Processes\n \nRevenue increased $5.9 billion or 9%.\n \n•\nOffice Commercial products and cloud services revenue increased $3.7 billion or 10%. Office 365 Commercial revenue grew 13% with seat\n \ngrowth of 11%, driven by small and medium business and frontline worker offerings, as well as growth in revenue per user. Office Commercial\n \nproducts revenue declined 21% driven by continued customer shift to cloud offerings.\n \n•\nOffice Consumer products and cloud services revenue increased $140 million or 2%. Microsoft 365 Consumer subscribers grew 12% to 67.0\n \nmillion.\n \n•\nLinkedIn revenue increased $1.3 billion or 10% driven by Talent Solutions.\n•\nDynamics products and cloud services revenue increased $750 million or 16% driven by Dynamics 365 growth of 24%.\n \nOperating income increased $4.5 billion or 15%.\n•\nGross margin increased $5.8 billion or 12% driven by growth in Office 365 Commercial and LinkedIn, as well as the change in accounting\n                        ExternalSourceName: \n                        Source: MICROSOFT\n                        AdditionalMetadata: 2023_10K_44_872\n                        \n\"\"\"\n\n\n\"\"\" ID: Mzky\n                        Text: PART II\nItem 8\n \nRevenue, classified by significant product and service offerings, was as follows:\n \n \n(In millions)\n \n \n \n \n \n \n \n \n \n \nYear Ended June 30,\n \n2023\n \n \n2022\n \n \n2021\n \n \n \n \n \nServer products and cloud services\n \n$\n79,970\n \n \n$\n67,350\n \n \n$\n52,589\n \nOffice products and cloud services\n \n \n48,728\n \n \n \n44,862\n \n \n \n39,872\n \nWindows\n \n \n21,507\n \n \n24,732\n \n \n \n22,488\n \nGaming\n \n \n15,466\n \n \n16,230\n \n \n \n15,370\n \nLinkedIn\n \n \n15,145\n \n \n \n13,816\n \n \n \n10,289\n \nSearch and news advertising\n \n \n12,208\n \n \n \n11,591\n \n \n \n9,267\n \nEnterprise Services\n \n \n7,722\n \n \n \n7,407\n \n \n \n6,943\n \nDevices\n \n \n5,521\n \n \n \n7,306\n \n \n \n7,143\n \nDynamics\n \n \n5,437\n \n \n4,687\n \n \n \n3,754\n \nOther\n \n \n211\n \n \n \n289\n \n \n \n373\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nTotal\n \n$\n211,915\n \n \n$\n198,270\n \n \n$\n168,088\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nOur Microsoft Cloud revenue, which includes Azure and other cloud services, Office 365 Commercial, the commercial portion of LinkedIn, Dynamics 365,\n                        ExternalSourceName: \n                        Source: MICROSOFT\n                        AdditionalMetadata: 2023_10K_94_0\n                        \n\"\"\"\n\n"
    },
    {
        "question": "In agreement with the information outlined in the income statement, what is average net profit margin (as a %) for Best Buy?",
        "documents": "No documents found"
    },
    {
        "question": "What is the total amount of inventories for Best Buy? Answer in USD millions. Base your judgments on the information provided primarily in the balance sheet.",
        "documents": "No documents found"
    },
    {
        "question": "Is growth in JnJ's adjusted EPS expected to accelerate?",
        "documents": "No documents found"
    },
    {
        "question": "How did JnJ's sales growth compare to international sales growth?",
        "documents": "No documents found"
    },
    {
        "question": "Has Microsoft increased its debt on balance sheet?",
        "documents": "\n\"\"\" ID: MTg1\n                        Text: manufacturing, marketing, and selling our other products and services; and income taxes.\nHighlights from fiscal year 2023 compared with fiscal year 2022 included:\n•\nMicrosoft Cloud revenue increased 22% to $111.6 billion.\n•\nOffice Commercial products and cloud services revenue increased 10% driven by Office 365 Commercial growth of 13%.\n•\nOffice Consumer products and cloud services revenue increased 2% and Microsoft 365 Consumer subscribers increased to 67.0 million.\n•\nLinkedIn revenue increased 10%.\n•\nDynamics products and cloud services revenue increased 16% driven by Dynamics 365 growth of 24%.\n•\nServer products and cloud services revenue increased 19% driven by Azure and other cloud services growth of 29%.\n•\nWindows original equipment manufacturer licensing (“Windows OEM”) revenue decreased 25%.\n•\nDevices revenue decreased 24%.\n•\nWindows Commercial products and cloud services revenue increased 5%.\n•\nXbox content and services revenue decreased 3%.\n \n•\n                        ExternalSourceName: \n                        Source: MICROSOFT\n                        AdditionalMetadata: 2023_10K_39_1959\n                        \n\"\"\"\n\n\n\"\"\" ID: Mzk1\n                        Text: PART II\nItem 8\n \nREPORT OF INDEPENDENT REGIST\nERED PUBLIC ACCOUNTING FIRM\nTo the Stockholders and the Board of Directors of Microsoft Corporation\n \nOpinion on the Financial Statements\nWe have audited the accompanying consolidated balance sheets of Microsoft Corporation and subsidiaries (the \"Company\") as of June 30, 2023\n \nand 2022, the related consolidated statements of income, comprehensive income, cash flows, and stockholders' equity, for each of the three\n \nyears in the period ended June 30, 2023, and the related notes (collectively referred to as the \"financial statements\"). In our opinion, the financial\n \nstatements present fairly, in all material respects, the financial position of the Company as of June 30, 2023 and 2022, and the results of its\n \noperations and its cash flows for each of the three years in the period ended June 30, 2023, in conformity with accounting principles generally\n \naccepted in the United States of America.\n                        ExternalSourceName: \n                        Source: MICROSOFT\n                        AdditionalMetadata: 2023_10K_95_0\n                        \n\"\"\"\n\n\n\"\"\" ID: MjAy\n                        Text: increased driven by Office 365 Commercial and LinkedIn. More Personal Computing revenue decreased driven by Windows  and Devices.\n \nCost of revenue increased $3.2 billion or 5% driven by growth in Microsoft Cloud\n,\n offset in part by the change in accounting estimate.\nGross margin increased $10.4 billion or 8% driven by growth in Intelligent Cloud and Productivity and Business Processes and the change in accounting\n \nestimate, offset in part by a decline in More Personal Computing.\n \n•\nGross margin percentage increased slightly. Excluding the impact of the change in accounting estimate, gross margin percentage decreased 1\n \npoint driven by declines in Intelligent Cloud and More Personal Computing, offset in part by sales mix shift between our segments.\n•\nMicrosoft Cloud gross margin percentage increased 2 points to 72%. Excluding the impact of the change in accounting estimate, Microsoft\n                        ExternalSourceName: \n                        Source: MICROSOFT\n                        AdditionalMetadata: 2023_10K_43_1884\n                        \n\"\"\"\n\n\n\"\"\" ID: NDI3\n                        Text: due 2047, and 4.500% Notes due 2057, dated\n \nas of February 6, 2017, between Microsoft\n \nCorporation and The Bank of New York Mellon\n \nTrust Company, N.A., as Trustee, to the\n \nIndenture, dated as of May 18, 2009, between\n \nMicrosoft Corporation and The Bank of New\n \nYork Mellon Trust Company, N.A., as trustee\n \n \n \n \n8-K\n \n \n \n \n \n \n \n4.1\n \n \n \n2/3/2017\n \n \n \n \n \n \n \n \n4.16\n \nThirteenth Supplemental Indenture for 2.525%\n \nNotes due 2050 and 2.675% Notes due 2060,\n \ndated as of June 1, 2020, between Microsoft\n \nCorporation and U.S. Bank National Association,\n \nas Trustee, to the Indenture, dated as of May 18,\n \n2009, between Microsoft Corporation and The\n \nBank of New York Mellon Trust Company, N.A.,\n \nas trustee\n \n \n \n \n8-K\n \n \n \n \n \n \n \n4.1\n \n \n \n6/1/2020\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n4.17\n \nFourteenth Supplemental Indenture for 2.921%\n \nNotes due 2052 and 3.041% Notes due 2062,\n \ndated as of March 17, 2021, between Microsoft\n \nCorporation and The Bank of New York Mellon\n                        ExternalSourceName: \n                        Source: MICROSOFT\n                        AdditionalMetadata: 2023_10K_104_935\n                        \n\"\"\"\n\n"
    },
    {
        "question": "How much does Pfizer expect to pay to spin off Upjohn in the future in USD million?",
        "documents": "\n\"\"\" ID: NzE0\n                        Text: OVERVIEW OF OUR PERFORMANCE, OPERATING ENVIRONMENT, STRATEGY AND OUTLOOK\nOur Business and Strategy––Pfizer Inc. is a research-based, global biopharmaceutical company. We apply science and our global resources to bring therapies\nto people that extend and significantly improve their lives. In 2023, we are making additional investments in both R&D and SI&A to support Pfizer’s near- and\nlonger-term growth plans, including to support anticipated new launches, commercial launch of COVID-19 products, potential pipeline programs and recently\nacquired assets. We manage our commercial operations through a global structure consisting of two operating segments: Biopharma and Business Innovation.\nBiopharma is the only reportable segment. See Note 13A.\nWe expect to incur costs of approximately $700 million in connection with separating Upjohn, of which approximately 90% has been incurred since inception\n                        ExternalSourceName: \n                        Source: PFIZER\n                        AdditionalMetadata: 2023_10Q_40_953\n                        \n\"\"\"\n\n\n\"\"\" ID: NTgx\n                        Text: ended July 2, 2023 and July 3, 2022, amounts recorded under interim agreements, including TSAs and MSAs, associated with these disposals were not\nmaterial. Under agreements related to the 2020 spin-off and the combination of the Upjohn Business with Mylan to form Viatris, net amounts due to Viatris\nwere $25 million as of July 2, 2023 and $94 million as of December 31, 2022. The cash flows associated with the agreements are included in Net cash provided\nby/(used in) operating activities. For information about the nature of these agreements, see Note 2B in our 2022 Form 10-K.\nC. Equity-Method Investment\nHaleon/Consumer Healthcare JV––On July 18, 2022, GSK completed a demerger of the Consumer Healthcare JV which became Haleon, an independent,\npublicly traded company listed on the London Stock Exchange that holds the joint historical\n11\n                        ExternalSourceName: \n                        Source: PFIZER\n                        AdditionalMetadata: 2023_10Q_13_4709\n                        \n\"\"\"\n\n\n\"\"\" ID: Nzk4\n                        Text: See Note 4.\nFor the second quarter of 2023, the total Other (income)/deductions––net adjustment of $171 million primarily includes charges of $139 million for certain legal matters, primarily representing\ncertain product liability and other legal expenses related to products discontinued and/or divested by Pfizer. For the first six months of 2023, the total Other (income)/deductions––net adjustment of\n$64 million primarily includes charges of (i) $175 million for certain legal matters, primarily for certain product liability and other legal expenses related to products discontinued and/or divested\nby Pfizer, and (ii) $70 million mostly related to our equity-method accounting pro-rata share of intangible asset amortization and impairments, costs of separating from GSK and restructuring costs\nrecorded by Haleon, partially offset by dividend income of $211 million related to our investment in Nimbus resulting from Takeda Pharmaceutical Company Limited’s acquisition of Nimbus’s\n                        ExternalSourceName: \n                        Source: PFIZER\n                        AdditionalMetadata: 2023_10Q_57_2833\n                        \n\"\"\"\n\n\n\"\"\" ID: NzE4\n                        Text: customary closing conditions.\nAgreement with Flagship Pioneering, Inc. (Flagship)––In July 2023, we and Flagship announced that we have partnered to create a new pipeline of innovative\nmedicines. Under the terms of the novel agreement, we and Flagship will each invest $50 million upfront to explore opportunities to develop 10 single-asset\nprograms by leveraging Flagship’s ecosystem of more than 40 human health companies and multiple biotechnology platforms. Pfizer will fund and have an\noption to acquire each selected development program. Flagship and its bioplatform companies will be eligible to receive up to $700 million in milestones and\nroyalties for each successfully commercialized program.\n38\n                        ExternalSourceName: \n                        Source: PFIZER\n                        AdditionalMetadata: 2023_10Q_40_4653\n                        \n\"\"\"\n\n"
    },
    {
        "question": "For Pfizer, which geographic region had the biggest drop in year over year revenues?",
        "documents": "\n\"\"\" ID: NzQx\n                        Text: Total revenues $ 31,015 $ 53,402 $ 14,692 $ 20,140 $ 16,323 $ 33,262 (42) (27) (51)\nSecond Quarter of 2023 vs. Second Quarter of 2022\nThe following provides an analysis of the change in worldwide revenues by geographic areas in the second quarter of 2023:\nThree Months Ended July 2, 2023\n(MILLIONS) Worldwide U.S. International\nOperational growth/(decline):\nWorldwide declines from Paxlovid $ (7,967) $ (4,455) $ (3,512)\nWorldwide declines from Comirnaty (7,294) (1,063) (6,230)\nLower revenues from Inflectra, primarily driven by lower net price in the U.S. as a result of unfavorable changes in\nchannel mix (62) (64) 2 \nRevenues from recently acquired products: Nurtec ODT/V ydura  and Oxbryta 324 319 4 \nWorldwide growth from the Vyndaqel family , Xeljanz, Eliquis and Xtandi, partially of fset by declines from Ibrance,\nthe Prevnar family and Inlyta 244 226 18 \nOther operational factors, net 31 — 30 \nOperational growth/(decline), net (14,725) (5,037) (9,688)\nUnfavorable impact of foreign exchange (283) — (283)\n                        ExternalSourceName: \n                        Source: PFIZER\n                        AdditionalMetadata: 2023_10Q_44_933\n                        \n\"\"\"\n\n\n\"\"\" ID: NzAx\n                        Text: Certain significant items are substantive and/or unusual, and in some cases recurring, items (as noted above). Earnings in the second quarter and first six months of 2022 included, among other\nitems, net losses on equity securities of $539 million and $1.2 billion, respectively, recorded in Other (income)/deductions––net. See Note 4.\nB. Geographic Information\nThe following summarizes revenues by geographic area:\n Three Months Ended Six Months Ended\n(MILLIONS)July 2,\n2023July 3,\n2022%\nChangeJuly 2,\n2023July 3,\n2022%\nChange\nUnited States $ 6,185 $ 11,222 (45)$ 14,692 $ 20,140 (27)\nDeveloped Europe 2,415 5,480 (56) 5,236 11,569 (55)\nDeveloped Rest of World 1,305 5,034 (74) 3,778 8,320 (55)\nEmerging Markets 2,828 6,006 (53) 7,308 13,373 (45)\nRevenues $ 12,734 $ 27,742 (54)$ 31,015 $ 53,402 (42)\nIn May 2023, we and our collaboration partner, BioNTech, amended our contract with the EC to deliver COVID-19 vaccines to the EU. The amended\n                        ExternalSourceName: \n                        Source: PFIZER\n                        AdditionalMetadata: 2023_10Q_37_2856\n                        \n\"\"\"\n\n\n\"\"\" ID: NzQ3\n                        Text: Revenues––Selected Product Discussion\nBiopharma\n(MILLIONS) Revenue % Change\nProduct PeriodGlobal\nRevenues Region July 2, 2023July 3, 2022 Total Oper. Operational Results Commentary\nComirnatyQTD$1,488\nDown 82%\n(operationally)U.S. $ 17 $ 1,080 (98)\nGlobal declines largely driven by lower contracted deliveries and demand in\ninternational markets and lower U.S. government contracted deliveries, with\nanticipated transition to new variant vaccines globally and to traditional U.S.\ncommercial market sales in the second half of 2023.Int’l. 1,471 7,768 (81) (80)\nWorldwide $ 1,488 $ 8,848 (83) (82)\nYTD$4,552\nDown 78%\n(operationally)U.S. $ 345 $ 3,395 (90)\nInt’l. 4,207 18,681 (77) (76)\nWorldwide $ 4,552 $ 22,075 (79) (78)\nPaxlovidQTD$143\nDown 98%\n(operationally)U.S. $ — $ 4,455 *\nDeclines primarily driven by:\n• No second quarter U.S. sales in anticipation of transition to traditional\ncommercial markets in the second half of 2023, and\n• lower contractual deliveries in most international markets\n                        ExternalSourceName: \n                        Source: PFIZER\n                        AdditionalMetadata: 2023_10Q_46_0\n                        \n\"\"\"\n\n\n\"\"\" ID: NzQz\n                        Text: First Six Months of 2023 vs. First Six Months of 2022\nThe following provides an analysis of the worldwide change in revenues by geographic areas in the first six months of 2023:\nSix Months Ended July 2, 2023\n(MILLIONS) Worldwide U.S. International\nOperational growth/(decline):\nWorldwide declines from Comirnaty $ (17,260) $ (3,049) $ (14,21 1)\nWorldwide declines from Paxlovid (5,214) (3,510) (1,704)\nRevenues from recently acquired products: Nurtec ODT/V ydura  and Oxbryta 561 553 8 \nWorldwide growth from the Vyndaqel family , Eliquis, the Prevnar family , Inlyta and Xtandi, partially of fset by\ndeclines from Ibrance and Xeljanz 363 477 (115)\nIncreased revenues from Sulperazon, lar gely driven by demand in China in the first quarter of 2023 114 — 114 \nOther operational factors, net 62 81 (19)\nOperational growth/(decline), net (21,374) (5,448) (15,926)\nUnfavorable impact of foreign exchange (1,013) — (1,013)\nRevenues  increase/(decrease) $ (22,387) $ (5,448) $ (16,939)\n                        ExternalSourceName: \n                        Source: PFIZER\n                        AdditionalMetadata: 2023_10Q_45_0\n                        \n\"\"\"\n\n"
    },
    {
        "question": "Is Pfizer spinning off any large business segments?",
        "documents": "\n\"\"\" ID: NzE0\n                        Text: OVERVIEW OF OUR PERFORMANCE, OPERATING ENVIRONMENT, STRATEGY AND OUTLOOK\nOur Business and Strategy––Pfizer Inc. is a research-based, global biopharmaceutical company. We apply science and our global resources to bring therapies\nto people that extend and significantly improve their lives. In 2023, we are making additional investments in both R&D and SI&A to support Pfizer’s near- and\nlonger-term growth plans, including to support anticipated new launches, commercial launch of COVID-19 products, potential pipeline programs and recently\nacquired assets. We manage our commercial operations through a global structure consisting of two operating segments: Biopharma and Business Innovation.\nBiopharma is the only reportable segment. See Note 13A.\nWe expect to incur costs of approximately $700 million in connection with separating Upjohn, of which approximately 90% has been incurred since inception\n                        ExternalSourceName: \n                        Source: PFIZER\n                        AdditionalMetadata: 2023_10Q_40_953\n                        \n\"\"\"\n\n\n\"\"\" ID: Njk1\n                        Text: 2022 Form 10-K.\nNote 13. Segment, Geographic and Other Revenue Information\nA. Segment Information\nWe manage our commercial operations through two operating segments, each led by a single manager: Biopharma and Business Innovation, an operating\nsegment established in the first quarter of 2023 that includes PC1, our contract development and manufacturing organization and a leading supplier of specialty\nactive pharmaceutical ingredients, and Pfizer Ignite, a recently launched offering that provides strategic guidance and end-to-end R&D services to select\ninnovative biotech companies that align with Pfizer’s R&D focus areas. Biopharma is the only reportable segment. Each operating segment has responsibility\nfor its commercial activities. Regional commercial organizations market, distribute and sell our products and are supported by global platform functions that\n                        ExternalSourceName: \n                        Source: PFIZER\n                        AdditionalMetadata: 2023_10Q_36_2789\n                        \n\"\"\"\n\n\n\"\"\" ID: NTcy\n                        Text: interim financial statements may not be representative of those for the full year.\nPfizer’s fiscal quarter-end for subsidiaries operating outside the U.S. is as of and for the three and six months ended May 28, 2023 and May 29, 2022, and for\nU.S. subsidiaries is as of and for the three and six months ended July 2, 2023 and July 3, 2022.\nWe manage our commercial operations through two operating segments, each led by a single manager: Biopharma and Business Innovation. Biopharma is the\nonly reportable segment. See Note 13A below and Note 17A in our 2022 Form 10-K.\nBusiness development activities impacted financial results in the periods presented. In March 2023, we and Seagen announced that the companies entered into\nan agreement under which we will acquire Seagen, a global biotechnology company that discovers, develops and commercializes transformative cancer\n                        ExternalSourceName: \n                        Source: PFIZER\n                        AdditionalMetadata: 2023_10Q_12_978\n                        \n\"\"\"\n\n\n\"\"\" ID: Njk4\n                        Text: PFIZER INC. AND SUBSIDIARY COMPANIES.\nNOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS\n(UNAUDITED)\nSegment Assets––We manage our assets on a total company basis, not by operating segment, as our operating assets are shared or commingled. Therefore, our\nchief operating decision maker does not regularly review any asset information by operating segment and, accordingly, we do not report asset information by\noperating segment. Total assets were $220 billion as of July 2, 2023 and $197 billion as of December 31, 2022.\nSelected Income Statement Information\nThe following provides selected income statement information by reportable segment:\nThree Months Ended Six Months Ended\n Revenues Earnings Revenues Earnings\n(MILLIONS)July 2,\n2023July 3,\n2022July 2,\n2023July 3,\n2022July 2,\n2023July 3,\n2022July 2,\n2023July 3,\n2022\nReportable Segment:\nBiopharma $ 12,418 $ 27,425 $ 7,003 $ 17,166 $ 30,389 $ 52,748 $ 17,939 $ 30,557 \nOther business activities 316 317 (2,871) (3,384) 626 655 (5,605) (5,812)\nReconciling Items:\n                        ExternalSourceName: \n                        Source: PFIZER\n                        AdditionalMetadata: 2023_10Q_37_0\n                        \n\"\"\"\n\n"
    }
]